NCT05429632 2026-04-17
MO-TRANS
Priothera SAS
Phase 3 Recruiting
Clinical Trials
52 trialsNCT04829539 2026-04-16
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment
University of Rochester
Phase 3 Recruiting
NCT06073821 2026-04-16
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
BeOne Medicines
Phase 3 Active not recruiting
NCT06846671 2026-04-16
CaDAnCe-302
BeOne Medicines
Phase 3 Recruiting
NCT07504458 2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3 Recruiting
NCT04269902 2026-04-15
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06943872 2026-04-15
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Medicines
Phase 3 Recruiting
NCT06973187 2026-04-15
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
BeOne Medicines
Phase 3 Recruiting
NCT07277231 2026-04-15
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 3 Recruiting
NCT00843882 2026-04-13
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01804686 2026-04-13
CAN3001
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT01886872 2026-04-13
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03462719 2026-04-13
GLOW
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT03486873 2026-04-13
MK-3475-587
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT03701282 2026-04-13
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03737981 2026-04-13
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03914625 2026-04-13
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04939090 2026-04-13
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT05327894 2026-04-13
Interfant-21
Princess Maxima Center for Pediatric Oncology
Phase 3 Recruiting
NCT05645107 2026-04-13
EXCELL
Grifols Therapeutics LLC
Phase 3 Recruiting
NCT06136559 2026-04-13
BELLWAVE-011
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06852222 2026-04-13
cAMeLot-2
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT07469046 2026-04-13
VAH vs VA in Newly Diagnosed Elderly AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 3 Not yet recruiting
NCT04547049 2026-04-09
A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies
First Affiliated Hospital of Zhejiang University
Phase 3 Active not recruiting
NCT06428019 2026-04-09
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
AbbVie
Phase 3 Recruiting
NCT07007312 2026-04-09
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Kura Oncology, Inc.
Phase 3 Recruiting
NCT01503632 2026-04-08
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
Children's Oncology Group
Phase 3 Completed
NCT04102020 2026-04-08
VIALE-M
AbbVie
Phase 3 Completed
NCT06713837 2026-04-08
IMPACT-AML
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 3 Recruiting
NCT07516093 2026-04-08
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Nurix Therapeutics, Inc.
Phase 3 Not yet recruiting
NCT04971226 2026-04-06
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Phase 3 Active not recruiting
NCT07223814 2026-04-06
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Recruiting
NCT07511127 2026-04-06
Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT
Ruijin Hospital
Phase 3 Recruiting
NCT01366612 2026-04-03
FLUBUTBI
Hackensack Meridian Health
Phase 3 Terminated
NCT07509151 2026-04-03
SOUNDTRACK-C1
AstraZeneca
Phase 3 Not yet recruiting
NCT00931645 2026-04-02
Auto-LLC 2001
University Hospital, Caen
Phase 3 Completed
NCT04094311 2026-04-02
Study of Out of Specification for Tisagenlecleucel
Novartis
Phase 3 Recruiting
NCT04628026 2026-04-02
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
University of Ulm
Phase 3 Recruiting
NCT05254743 2026-04-01
BRUIN-CLL-314
Eli Lilly and Company
Phase 3 Recruiting
NCT01190930 2026-03-31
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Children's Oncology Group
Phase 3 Active not recruiting
NCT03959085 2026-03-31
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Children's Oncology Group
Phase 3 Recruiting
NCT06578247 2026-03-31
QuANTUM-WILD
Daiichi Sankyo
Phase 3 Recruiting
NCT02477696 2026-03-27
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
Phase 3 Active not recruiting
NCT04307576 2026-03-27
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Karolinska University Hospital
Phase 3 Recruiting
NCT07139873 2026-03-27
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Dizal Pharmaceuticals
Phase 3 Recruiting
NCT07211958 2026-03-25
REVEAL-ND NPM1
Syndax Pharmaceuticals
Phase 3 Recruiting
NCT07407140 2026-03-25
VAG-3+7-G
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Not yet recruiting
NCT07485855 2026-03-24
(HEM-FLU)
Asan Medical Center
Phase 3 Recruiting
NCT07489755 2026-03-24
TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients
Shenzhen TargetRx Co., Ltd.
Phase 3 Not yet recruiting
NCT03844048 2026-03-20
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie
Phase 3 Active not recruiting